Dr. Hofmeister Discusses Checkpoint Inhibitors in Myeloma

Craig Hofmeister, MD
Published: Wednesday, Nov 15, 2017



Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.

A trial of durvalumab (Imfinzi) and lenalidomide (Revlimid) with and without low-dose dexamethasone in patients with newly diagnosed multiple myeloma, and three other studies exploring durvalumab in multiple myeloma—MEDI4736-MM-001, MEDI4736-MM-003, and MEDI4736-MM-005—were placed on partial hold earlier in 2017.

Hofmeister hopes that with further testing they will be incorporated as relapsed, and ultimately upfront therapy for patients with multiple myeloma.
 
SELECTED
LANGUAGE


Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.

A trial of durvalumab (Imfinzi) and lenalidomide (Revlimid) with and without low-dose dexamethasone in patients with newly diagnosed multiple myeloma, and three other studies exploring durvalumab in multiple myeloma—MEDI4736-MM-001, MEDI4736-MM-003, and MEDI4736-MM-005—were placed on partial hold earlier in 2017.

Hofmeister hopes that with further testing they will be incorporated as relapsed, and ultimately upfront therapy for patients with multiple myeloma.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x